MarketCap
Facebook
X
Telegram
Blonder Tongue Laboratories Balance Sheet 2022-2009 | BDR
Brief overview of Blonder Tongue Laboratories's assets and capital
The comparison uses five available annual reports from the 2018–2022 interval.
Assets changed little, standing at $15.6 million initially and $15 million at the end. The balance sheet stayed close to its former scale.
Liabilities grew faster than assets: +65.2% versus -3.8%. A substantial part of expansion was externally funded.
Equity funds just 7.2% of assets versus 45.9% previously. The balance sheet is sensitive to weaker results.
Net debt stands at $4.6 million, or 4.27x of equity. The debt cushion is limited.
Cash accounts for 0.5% of assets versus 3.6% initially. The change indicates the degree of financial flexibility.
The balance sheet includes a negative accumulated result of -$30.2 million. It should be assessed alongside historical profits and capital distributions.
Overall picture
Blonder Tongue Laboratories's financial structure calls for caution. Stronger equity, lower debt or restored liquidity would be needed to improve it.
Annual Balance Sheet Blonder Tongue Laboratories
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
4.58 M | 1.54 M | 1.76 M | -492 K | 2.55 M | 3.18 M | 3.1 M | 3.6 M | 3.66 M | 4.1 M | 3.99 M | 2.23 M | 1.39 M | - |
Long Term Debt |
4.09 M | 993 K | 1.8 M | 47 K | 32 K | 3.09 M | 3.34 M | 10 K | 3.61 M | 3.89 M | 4.16 M | 2.82 M | 2.87 M | - |
Long Term Debt Current |
569 K | 826 K | 28 K | 33 K | 3.08 M | 249 K | 228 K | 3.6 M | 286 K | 270 K | 277 K | 258 K | 235 K | - |
Total Non Current Liabilities |
- | - | 4.36 M | 2.62 M | 171 K | 3.82 M | 3.85 M | 239 K | 3.7 M | 3.96 M | 4.19 M | 2.82 M | - | - |
Total Current Liabilities |
8.16 M | 6.06 M | 5.53 M | 8.37 M | 8.26 M | 3.94 M | 4.62 M | 8.62 M | 3.8 M | 3.66 M | 5.48 M | 1.85 M | 1.7 M | - |
Total Liabilities |
13.9 M | 8.62 M | 9.89 M | 11 M | 8.43 M | 7.76 M | 8.47 M | 8.86 M | 7.51 M | 7.61 M | 9.68 M | 4.67 M | - | - |
Retained Earnings |
-30.2 M | -27.3 M | -27.4 M | -19.9 M | -19.2 M | -17.8 M | -17.2 M | -12.2 M | -4.1 M | -3.19 M | -372 K | 4.78 M | 5.2 M | - |
Total Assets |
15 M | 11.9 M | 11.1 M | 18.3 M | 15.6 M | 15.2 M | 15 M | 16.2 M | 21.2 M | 22.6 M | 26.3 M | 25.9 M | 26.6 M | - |
Cash and Cash Equivalents |
79 K | 274 K | 69 K | 572 K | 559 K | 168 K | 468 K | 9 K | 232 K | 67 K | 453 K | 851 K | 1.72 M | 14 K |
Book Value |
1.07 M | 3.28 M | 1.24 M | 7.36 M | 7.17 M | 7.41 M | 6.53 M | 7.37 M | 13.7 M | 15 M | 16.6 M | 21.2 M | 26.6 M | - |
Total Shareholders Equity |
1.07 M | 3.28 M | 1.24 M | 7.36 M | 7.17 M | 7.41 M | 6.53 M | 7.37 M | 13.7 M | 15 M | 16.6 M | 21.2 M | 22 M | 20.2 M |
All numbers in USD currency
Quarterly Balance Sheet Blonder Tongue Laboratories
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | 4.24 M | 549 K | - | 993 K | - | - | - | 1.8 M | - | - | 41 K | 47 K | 45 K | 24 K | 30 K | 32 K | 2.92 M | 2.98 M | 3.04 M | 3.09 M | 3.16 M | 3.21 M | 3.27 M | 3.34 M | 52 K | 2 K | 3 K | 10 K | 14 K | 12 K | 25 K | 3.61 M | 59 K | 76 K | 93 K | 3.89 M | 3.96 M | 4.02 M | 4.09 M | 4.16 M | 4.21 M | 4.28 M | 4.16 M | 2.82 M | 2.82 M | 2.82 M | 2.82 M |
Total Liabilities |
- | 14.3 M | 10.8 M | 9.12 M | 8.62 M | 8.38 M | 8.42 M | 9.62 M | 9.89 M | 10.9 M | 12.3 M | 11.2 M | 11 M | 7.49 M | 6.67 M | 5.36 M | 8.43 M | 7.7 M | 7.02 M | 7.8 M | 7.76 M | 8.59 M | 8.11 M | 8.34 M | 8.47 M | 8.47 M | 8.47 M | 8.47 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | -30.3 M | -29.6 M | -28.5 M | -27.3 M | -26.4 M | -26.2 M | -27.8 M | -27.4 M | -25 M | -23.2 M | -22 M | -19.9 M | -16.1 M | -14.7 M | -13.9 M | -19.2 M | -18.4 M | -18.2 M | -17.9 M | -17.8 M | -17.8 M | -17.7 M | -17.4 M | -17.2 M | -16.8 M | -14.2 M | -12.5 M | -12.2 M | -9.47 M | -6.77 M | -5.51 M | -4.1 M | -3.42 M | -4.01 M | -4.36 M | -3.19 M | -2.2 M | -1.51 M | -854 K | -372 K | 2.81 M | 2.72 M | -372 K | 4.78 M | 4.78 M | 4.78 M | 4.78 M |
Total Assets |
- | 15.3 M | 12.3 M | 11.5 M | 11.9 M | 12.1 M | 11.9 M | 11.1 M | 11.1 M | 13.5 M | 16.6 M | 16.6 M | 18.3 M | 18.5 M | 18.8 M | 18.1 M | 15.6 M | 15.4 M | 14.7 M | 15.2 M | 15.2 M | 15.2 M | 14.7 M | 15.1 M | 15 M | 14.8 M | 15.6 M | 17.2 M | 16.2 M | 18.6 M | 20.4 M | 21.6 M | 21.2 M | 22.4 M | 23.2 M | 21.5 M | 22.6 M | 22.9 M | 24.2 M | 25 M | 26.3 M | 30.9 M | 31.6 M | 26.3 M | 25.9 M | 25.9 M | 25.9 M | 25.9 M |
Cash and Cash Equivalents |
- | 167 K | 361 K | 110 K | 274 K | 271 K | 344 K | 56 K | 69 K | 75 K | 465 K | 79 K | 572 K | 369 K | 212 K | 1.63 M | 559 K | 96 K | 444 K | 238 K | 168 K | 199 K | 361 K | 543 K | 468 K | 213 K | 307 K | 513 K | 9 K | 304 K | 25 K | 94 K | 232 K | 1.43 M | 49 K | 113 K | 67 K | 54 K | 173 K | 78 K | 453 K | 170 K | 211 K | 453 K | 851 K | 851 K | 851 K | 851 K |
Book Value |
- | 937 K | 1.47 M | 2.41 M | 3.28 M | 3.76 M | 3.49 M | 1.5 M | 1.24 M | 2.61 M | 4.3 M | 5.4 M | 7.36 M | 11 M | 12.1 M | 12.8 M | 7.17 M | 7.68 M | 7.7 M | 7.43 M | 7.41 M | 6.59 M | 6.6 M | 6.76 M | 6.53 M | 6.36 M | 7.1 M | 8.73 M | 16.2 M | 18.6 M | 20.4 M | 21.6 M | 21.2 M | 22.4 M | 23.2 M | 21.5 M | 22.6 M | 22.9 M | 24.2 M | 25 M | 26.3 M | 30.9 M | 31.6 M | 26.3 M | 25.9 M | 25.9 M | 25.9 M | 25.9 M |
Total Shareholders Equity |
- | 937 K | 1.47 M | 2.41 M | 3.28 M | 3.76 M | 3.49 M | 1.5 M | 1.24 M | 2.61 M | 4.3 M | 5.4 M | 7.36 M | 11 M | 12.1 M | 12.8 M | 7.17 M | 7.68 M | 7.7 M | 7.43 M | 7.41 M | 6.59 M | 6.6 M | 6.76 M | 6.53 M | 6.89 M | 7.48 M | 7.13 M | 7.37 M | 9.26 M | 11.2 M | 12.4 M | 13.7 M | 15 M | 14.3 M | 13.9 M | 15 M | 15 M | 15.6 M | 16.2 M | 16.6 M | 19.4 M | 19.2 M | 16.6 M | 21.2 M | 21.2 M | 21.2 M | 21.2 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Blonder Tongue Laboratories, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Russia
Cayman-islands
Israel
Canada
Finland
